Skip to main content

Oncology news

21-09-2016 | Prostate cancer | Highlight | Article

Editor's pick

ProtecT clinical, patient-reported outcomes revealed

Two articles published in The New England Journal of Medicine report on the clinical and patient-reported outcomes of the ProtecT trial’s assessment of three approaches for the management of localised prostate cancer detected by prostate-specific antigen testing.


N Engl J Med 2016; Advance online publication

23-09-2016 | Oncology | News | Article

Prognostic value of MRD status in multiple myeloma confirmed

Post-treatment minimal residual disease status can serve as a marker of long-term survival in patients with newly diagnosed multiple myeloma, shows a meta-analysis.


JAMA Oncol 2016; Advance online publication

22-09-2016 | Colorectal cancer | News | Article

News in brief

Adverse African–American CRC outcomes may have genetic basis

The disparity in colorectal cancer clinical outcomes between African–American patients and those of other ethnicities could be down to a panel of 15 genes.

20-09-2016 | Melanoma | News | Article

News in brief

High factor sunscreen protects against melanoma

Using sunscreen with a sun protection factor of at least 15 may be key to reducing the risk of melanoma.

19-09-2016 | Leukaemia | News | Article

Rituximab addition benefits adult ALL patients

Addition of rituximab to a standard chemotherapeutic regimen boosts outcomes for adult patients with B-lineage, CD20-positive acute lymphoblastic leukaemia, trial findings indicate.


N Engl J Med 2016; 375: 1044–1053

QUASAR 2 Findings End Adjuvant Bevacizumab Use In Stage II/III CRC

Negative disease-free survival results for stage III or high-risk stage II colorectal cancer add to evidence against adjuvant bevacizumab in this setting

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).

approvalsWatch: Oncology



medwireNews brings you coverage of the 2015 European Cancer Congress, held in Vienna, Austria.

Click through to read the full reports of the latest research.

Twitter Icon Follow medwireNews

Click here
image credits